PlainPharmaWatch

CMS Open Payments · Tool

Kowa Pharmaceuticals America, Inc. vs BioPro, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

BioPro, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,788, versus 3 for the other company. Its single largest recorded recipient represents 0.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Kowa Pharmaceuticals America, Inc.
HHI 3 · top recipient 0.0%
Ranked #1,837 of 1,838 companies by HHI
BioPro, Inc.
HHI 1,788 · top recipient 0.3%
Ranked #792 of 1,838 companies by HHI

Payment Overview

Total Payments
$101.9K
% of Industry
0.0%
Transactions
5,883
Avg per Transaction
$17.32
Recipients
5,883
Avg per Recipient
$17.32
Payment Types
1
Top Payment Type
Food and Beverage
Company B

BioPro, Inc.

Total Payments
$101.9K
% of Industry
0.0%
Transactions
145
Avg per Transaction
$702.72
Recipients
145
Avg per Recipient
$702.72
Payment Types
7
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

Kowa Pharmaceuticals America, Inc. vs BioPro, Inc. - total reported payments in CMS Open Payments PY2024

Kowa Pharmaceuticals Americ…$101.9KBioPro, Inc.$101.9K

Payment Types Breakdown

Kowa Pharmaceuticals America, Inc.

Food and Beverage $101.9K

100.0%

BioPro, Inc.

Royalty or License $42.0K

41.2%

Consulting Fee $30.3K

29.7%

Honoraria $15.2K

14.9%

Food and Beverage $7.6K

7.5%

Travel and Lodging $6.0K

5.9%

Education $800.00

0.8%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Kowa Pharmaceuticals America, Inc.

  1. 1

    BASHAB BANERJI

    $400.65 · 4 txns

  2. 2

    ANTHONY CADIENTE HERNANDEZ

    $254.15 · 11 txns

  3. 3

    SHAWN DHILLON

    $229.37 · 6 txns

  4. 4

    VASUMATHY KUMARESAN

    $195.14 · 12 txns

  5. 5

    BRIAN KURONYA

    $193.53 · 12 txns

BioPro, Inc.

  1. 1

    Louis Habryl

    $34,781.04 · 17 txns

  2. 2

    Alejandro Badia

    $14,059.98 · 23 txns

  3. 3

    John Faillace

    $13,921.42 · 36 txns

  4. 4

    Gary Katz

    $10,969.84 · 12 txns

  5. 5

    Diego Miranda

    $6,464.84 · 5 txns

Summary Comparison

Metric Kowa Pharmaceuticals America, Inc. BioPro, Inc.
Total Payments $101.9K $101.9K
% of Industry Total 0.0% 0.0%
Transaction Count 5,883 145
Avg per Transaction $17.32 $702.72
Recipient Count 5,883 145
Avg per Recipient $17.32 $702.72
Payment Type Count 1 7
Top Payment Type Food and Beverage Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.